BTK inhibitors have been developed to treat B-cell malignancies and autoimmune diseases including multiple sclerosis (MS) (3, 4), where it is postulated that inhibiting BTK blocks the maturation of B cells (5–9). Here, BTK is linked to myeloid sarcoma.